GlassScriptPhysician profile
Aileen K Wang
NPI 1801167887
$6,428.97
in general payments reported to CMS, 2019-2025
31 companies · $1,473 in 2025
The $1,473 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,480 · 2020: $807 · 2021: $898 · 2022: $1,112 · 2023: $168 · 2024: $492 · 2025: $1,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169 · Travel and Lodging: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.79 |
| Travel and Lodging | $963.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $969.81 | 2025 | |
| Amgen INC. | $843.29 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbott Laboratories | $800.07 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $524.92 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $503.06 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $469.70 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $301.31 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $282.27 | 2019-2022 | |
| Novo Nordisk INC | $260.84 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $163.51 | 2019 | |
| Xeris Pharmaceuticals, INC. | $153.16 | 2020-2025 | Gvoke Hypopen |
| Mannkind Corporation | $125.46 | 2019-2025 | |
| Corcept Therapeutics | $117.61 | 2021 | |
| Becton, Dickinson and Company | $114.84 | 2021 | |
| Novartis Pharmaceuticals Corporation | $107.79 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $88.53 | 2019-2020 | |
| Glaxosmithkline, LLC. | $78.17 | 2019 | |
| Beta Bionics, INC. | $76.48 | 2024 | Ilet Bionic Pancreas |
| Alexion Pharmaceuticals, INC. | $75.22 | 2019-2020 | |
| Abbvie INC. | $71.13 | 2021-2022 | |
| Radius Health, INC. | $60.43 | 2024-2025 | Tymlos |
| Medtronic, INC. | $42.77 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $35.37 | 2025 | Yorvipath |
| Soleno Therapeutics, INC. | $26.04 | 2025 | Vykat Xr |
| Kyowa Kirin, INC. | $25.15 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.16 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $20.95 | 2025 | |
| Smith+Nephew, INC. | $17.77 | 2019 | |
| Ibsa Pharma INC. | $17.60 | 2020 | |
| Rgh Enterprises LLC | $17.60 | 2025 | |
| Currax Pharmaceuticals LLC | $16.96 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aileen Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.